des: A Comparitive Immunohistochemical Study of T Cell Markers Using a Novel Anti_CD7Antibody. "Applied Immunohistochemistry and Molecular Morphology 14(3) :291-295.
[0172] Dhar, S. , Gu, F. X. , Langer, R. , Farokhzad, 0. C. , and Lippard, S. J. (2008) ·''Targeted Delivery of Cisplatin to Prostate Cancer Cells by Aptamer Functionalized Pt (IV) Prodrug-PLGA-PEG Nanoparticles· ''Proceedings of the National Academy of Sciences 105 (45):17356-17361.
[0173] Ellington，A. D.，and Szostak，J. W. (1990) · "In vitro selection of RNA molecules that bind specific ligands. ^Nature 346:818-822.
[0174] Frankel，A. E.，J. H. Laver，et al· (1997) · "Therapy of Patients with T Cell Lymphomas and Leukemas Using an Anti_CD7 Monoclonal Antibody-Rich Chain Immunotoxin. ^Leukemia and Lymphoma 26(3):287-298.
[0175] Hall, T. A. (1999). ^BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. . ^Nucl. Acids. Symp. Ser.41 95-98..
[0176] Hao，Q.，J.Zhu，et al· (2001). ''Identification of a Novel，Human Multilymphoid Projenitor in Cord Blood. "Blood 97:3683-3690.
[0177] Huang，Z.，W. Pei，et al· (2009) · "One RNA aptamer sequence，two structures:a collaborating pair that inhibits AMP A receptors. "Nucleic Acids Res 37(12) :4022-4032.
[0178] Khati，M. (2010) · 〃The future of aptamers in medicine,Clinical Pathology 63(6) :480-487.
[0179] Khati，M.，Schuman，M.，Ibrahim，J.，Sattentau，Q.，Gordon，S.，and James, ff. (2003) ·''Neutralisation of Infectivity of Diverse R5 Clinical Isolates of Human Immunodeficiency Virus Type 1 by gpl20_Binding29 F-RNA Aptamers. ''Journal of Virology 77(23):12692-12698.
[0180] Kumar, P. , Ban, H. , Kim, S. , ffu, H. , Pearson, T. , Greiner, D. L. , Laour, A. , Yao, J., Haridas, V. , Habiro, K. , Yang, Y. , Jeong, J. , Lee, K. , Kim, Y. , Kim, S. ff. , Peipp, M. , Fey, G. H.，Manjunath，N.，Shultz，L. D.，Lee，S.，and Shankar，P. (2008) · 〃T Cell-Specific siRNA Delivery Suppressed HIV-1 Infection in Humanised Mice,Cell 134:577-586.
[0181] Lazarovits，A. I.，N. Osman，et al· (1994) · "CD7 is Associated with CD3 and CD45 on Human T Cells.''Journal of Immunology 153 (9) : 3956-3966.
[0182] Lobac, D. F. , L. L. Hensley, et al· (1985) ·''Human T Cell Antigen Expression During Early Stages of Fetal Thymic Maturation."Journal of Immunology 135(3) :1752-1759.
[0183] Man，Η· _Υ·，J. W. Lin，et al. (2000) · "Regulation of AMPA Receptor - Mediated Synaptic Transmission by Clathrin-Dependent Receptor Internalization. ''Neuron 25(3) :649-662.
[0184] McNamara, J. 0. , Andrechek, E. R. , Wang, Y. , Viles, K. D. , Rempel, R. E.,Gilbpa,E. ,Sullenger, B. A. , and Giangrande，R. H. (2006)·"Cell type-specific delivery of siRNAs with siRNA chimeras. "Nature Biotechnolgy 24(8):1005-1015.
[0185] Murphy，R. L.，and Smith，W. J. (2002) · "Switch studies:a review. "Reviews in Antiretroviral Therapy 3:146-155.
[0186] Neff，C. P.，J. Zhou，et al. (2011) · "An Aptamer-siRNA Chimera Suppresses HIV-lViral Loads and Protects from Helper CD4+T Cell Decline in Humanized Mice.''Science Translational Medicine 3 (66) :66ra66.
[0187] Neves, M. A. D. , 0. Reinstein, et al· (2010). "Defining a Stem Length-Dependent Binding Mechanism for the Cocaine-Binding Aptamer. A Combined NMR and Calorimetry Study. "Biochemistry 49(39) :8478-8487.
[0188] Nguyen, T. , R. Pei, et al. (2011). ^Label-free microfluidic characterization of temperature-dependent biomolecular interactions. "Biomicrofluidics 5(3) :34118-341187.
[0189] Peipp，Μ.，H. Kupers，et al· (2002) · "A Recombinant CD7_Specif ic Single-Chain Immunotoxin is a Potent Inducer of Apoptosis in Acute Leukemic Cells. "Cancer Research 62:2848-2855.
[0190] Sempowski，G. D.，D. M. Lee，et al· (1999) · "Structure and Function of the CD7Molecule. "Critical Reviews in Immunology 19(4):331-348.
[0191] Stillwell，R. and B. E. Bierer (2001) · "T Cell Signal Transduction and the Role of CD7in Costimulation·''Immunologic Research 24 (1) : 31-52.
[0192] Teurk，C. and L. Gold (1990) · "Systematic Evolution of Ligands by Exponential Enrichment:RNA Ligands to Bacteriophage T4 DNA Polymerase.''Science 249:505-510.
[0193] Thiel, K. ff. , L. I. Hernandez, et al· (2012) · "Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers. ''Nucleic Acids Research 40(13) :6319-6337.
[0194] UNAIDS (2009). "AIDS Epidemic Update."
[0195] Vallera, D. A. , L. J. Burns, et al. (1996). ^Laboratory Preparation of a Declosylated Ricin Toxin A Chain Containing Immunotoxin Directed Against a CD7 T Lineage Differentiation Antigen for Phase I Human Clinical Studies Involving T Cell Malignancies.''Journal of Immunological Methods 197:69-83.
[0196] ffaurzyniak, B. , E. A. Schneider, et al· (1997)·〃In vivo Toxicity,Pharmacokinetics and Antileukemic Activity of TXU(Anti-CD7)-Pokeweed Antiviral Protein Immunotoxin.''Clinical Cancer Research 3:881-890.
[0197] Zhai，G.，Μ· Iskandar，et al. (2001) · "Characterization of RNA Aptamer Binding by the Wilms'Tumor Suppressor Protein WT1f."Biochemistry 40(7) :2032-2040.
[0198] Zhou，J.，P. Swiderski，et al· (2009) · "Selection，characterisation and application of new RNA HIV gpl20 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. "Nucleic Acid research 37(9):3094-3109.
[0199] Zhu，Q.，T. Shibata，et al· (2012) · "Inhibition of HIV-1 protease expression in T cells owing to DNA aptamer-mediated specific delivery of siRNA. ^Eur J Med Chem.
【主权项】
1.长度不超过100个核苷酸的适配体分子，其包含与序列5' GGGAGACAAGAAUAAGCAUG-R 1-UUCGACAGGAGGCUCACAACAGGC3'（SEQIDN0:3)具有至少80%同一性的核苷酸序列， 其中&为η x，其中每个η代表任意核苷酸且X为20至55的整数，并且 其中，所述适配体分子能够选择性结合于表达CD7受体的细胞。2.根据权利要求1所述的适配体分子，其具有与序列5' GGGAGACAAGAAUAAGCAUG-RfUUCGACAGGAGGCUCACAACAGG 3'（SEQ ID ΝΟ:123)或5' GGGAGACAAGAAUAAGCAUG-RfUUCGACAGGAGGCUCACAACAG 3'（SEQ ID ΝΟ:124)具有至少 80 %同一性的核苷酸序列。3.根据权利要求1或2所述的适配体分子，其中，X为29至55。4.根据权利要求1至3中任一项所述的适配体分子，其中，X为39至55。5.根据权利要求1至3中任一项所述的适配体分子，其中，X为39至49。6.根据权利要求1至6中任一项所述的适配体分子，其包含至少68个核苷酸。7.根据权利要求1至6中任一项所述的适配体分子，其包含至少80个核苷酸。8.根据权利要求1至7中任一项所述的适配体分子，其由84至90个核苷酸组成。9.根据权利要求1至8中任一项所述的适配体分子，其与SEQ ID NO: 3具有至少90% 的同一"性。10.根据权利要求1至9中任一项所述的适配体分子，其与SEQ ID NO: 3具有至少95% 的同一"性。11.根据权利要求1至10中任一项所述的适配体分子，包含SEQ ID NO: 3的核酸序列。12.根据权利要求1至11中任一项所述的适配体分子，其中，R i为： 5' -AGAGAUUUUGGGAAGGCUCAGGACUGCCUACUAACCCGAUAAGAAUUC-3' （SEQ ID N0:40); 5' -GGACCCCAACUAGCGUGUCAUUGUUCGAAUCGACUGAGAUUUCGGGUUC(SEQ ID N0:6); 5' -GAGUGCGUCGCCACUACUCCUCUCAUUACCUCUUGCAUUUCACUAUUC-3' （SEQ ID N0:26); 5' -CAGGUCCCACCGCCCCGCUCCCUUAUCAGCUUGGAAUACGUUUUCAUUC-3' （SEQ ID N0:56); 5' -AAACCCCAACUCUGGCGCACAUUUCCCCGCCACCACCGUAGAAUACUUC-3' （SEQ ID N0:4); 5' _CCCUUCCCUAGAACGCAGGCAGCAGUUACUCGGAGAACCCUACCCUUC(SEQ ID N0:5); 5' -AGACUGAUCCAAAUACGACACAAAUACCCGGCACUAGACGUUC-3' （SEQ ID N0:7); 5' -AGCAUCAAUCUAGACUAGACUCAGAUUACCAGCGAACUAGUGUAUCUUC-3' （SEQ ID N0:8); 5' -UAAUUCCAGCAUAAAAAAGAUAGGUACUAUUAAUACACGACCAGAAUUC-3' （SEQ ID N0:9); 5' -AUCUACGCGACCACAAAAUUAUCCGCGAUUUGAAUAUUC-3' （SEQ ID N0:10); 5' -CCCCUUGCGGUUCCCACAUUAUCUCUCUGCUAUCCCGAUGGCCCGAUUC-3' （SEQ ID N0:11); 5' -AGACAUUCUCUCCGCCCUCAACUCCGCCCGCUCCAUCCAGUUCCCUGUC-3' （SEQ ID N0:12); 5' -GCCGAUCCAUCCUCCCCACGACCAUCAUGAAUCCCAACAGGAACUUC-3' （SEQ ID N0:13); 5' -GGAUAGUUCUGCGUAGCUUAAGAGAUGUUAAAUCACACCCACGCCAUUC-3' （SEQ ID N0:14); 5' -GCUAUCAUACCCGAGACCGCUAUCCCCCACCUUAAUGUUCCUUC-3' （SEQ ID N0:15); 5' -AGACCGUACACCUCGCUCGCCAUCCGACUUUGAAUAAGCAUAGACCUUC-3' （SEQ ID N0:16); 5' -AGCGCCAAUAUGACCGCGACAUCGUUUGAAUAGUUCCUGGGGAUCUUUC-3' （SEQ ID N0:17); 5' -CCGGAUAAG⑶CGUCCGUAGUACCG⑶UAACGUACCAGCCUUACUCUUC-3'（SEQIDN0:18); 5' -AUCUAAAGACAGAUUUAAUACUACCCGUCGUAUCCAACUCGGAACG⑶C-3' （SEQ ID N0:19); 5'-UACGUAGACAAGAGAUUUCCAGACCCUCTJUACUAAUACAUUUCCCGUUC-3'（SEQIDN0:20); 5' -CUCUGACAAUCCUGCAACAAUUACAUUCAUUAACGGGCUAAUUCAUAUC-3' （SEQ ID N0:22); 5' -AUAUGUAGUAACCCCAAUGAUAAAUAACUAAGACCGCAA⑶CA⑶UCC-3' （SEQ ID N0:23); 5' -CCACUCCCACACUUCCUUAAUCCGCGCUAACACACCAUAUGUACUUC-3' （SEQ ID N0:24); 5' _CGUUAGCAGAUACAUCGAGAUUGCAAAGUCCAAUACAGUUAAUAAGUUC_3' （SEQ ID N0:25); 5' -CCCCACCCCACUAUUAGCCGAACCCGAACCCCAUCUUACCCGGACCC-3' （SEQ ID N0:27); 5' -UUCUCUGCGGUCUAGGUCACGAUAUACCCGUUACAUAUCAUUCCUGUUC-3' （SEQ ID N0:28); 5' -UACAAAUCCGCAUAUACACCCAACCACACCCAAUCCUCUCAGUCCAUUC-3' （SEQ ID N0:29); 5' -CCCUAGCAACAUUCUAUGCGCAAACCAUA⑶UAUGACUAUUGACUCUUC-3' （SEQ ID N0:30); 5' -CACACCGGCUGAGUAUCUGCCUGUGUAAUCGAAACAACUGCGACAUUC-3' （SEQ ID N0:31); 5' -CCGCACCCGUACCUCCUUCCUCUCAGGUAUUCACUCACAUCAUUUC-3' （SEQ